Ollin Biosciences, Inc. clinical trials
The registry lists 5 studies whose lead sponsor is Ollin Biosciences, Inc.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 5studies on the registry
- 4open to participants now
- 4phase 3 studies under way
Get an email when these change. Save the Ollin Biosciences, Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 1 programme
Each counted once: 1 with a study Ollin Biosciences, Inc. leads registered in the last two years.
- Phase 3
The 1 phase-3 programme — sign in to see them, free: with every programme, filter by condition or phase and sort by first study or next readout.
The 1 programme — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or next readout.
New in the registry
A programme's first Ollin Biosciences, Inc. study in the last 90 days, by the day it was submitted.
None in the last 90 days.
Moved up a phase
Ollin Biosciences, Inc.'s first study at a higher phase in the last 90 days, of a programme already under way.
- Sep 7OLN324 · Macular Degenerationto Phase 3
“Registry” is the highest phase of Ollin Biosciences, Inc.’s own registered studies; Ollin Biosciences, Inc.’s own pipeline document is not read yet. “Next readout” is the earliest primary completion date still ahead among its live studies, as the registry states it (most are estimates). Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Ollin Biosciences, Inc.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 25
- 426
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Ollin Biosciences, Inc..
- Ollin Biosciences, Inc.5 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 5 of 5.
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)Not yet recruitingNCT07841899Phase 3
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)Not yet recruitingNCT07842016Phase 3
- Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)Not yet recruitingNCT07816315Phase 3
- Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)Not yet recruitingNCT07816289Phase 3
- A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324CompletedNCT07484074Phase 1